CELU CELU
Company Profile ↓Company Overview
CELU (CELU) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 13.2% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $26.55M (-51.0% YoY); net profit $-91.72M.
- Trailing 12 Months Year-on-year growth — revenue -51.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 13.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 13.21% |
| 1 Year: | -51.03% |
Stock Price Performance
| 1 Year: | -76.77% |
| 6 Months: | -40.31% |
| 3 Months: | -22.96% |
| 1 Month: | +0.99% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)50.09 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 13.2% over 5 years.
CONS
- Trading 82.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 3.35M | 2.66M | 3.20M | 10.62M | 5.93M | 3.78M | 4.13M | 3.94M | 2.94M | 3.79M | 14.68M | 12.11M | 9.30M | 11.43M | 5.74M | 5.28M |
| Gross Profit | - | - | - | - | - | 2.32M | 1.42M | 1.76M | 8.31M | 1.91M | 597.00K | -3.08M | 1.93M | 2.14M | 184.00K | - | - | - | - | - | - |
| Operating Income | -121 | -115.25K | -202.00K | -241.64K | -208.23K | -4.81M | -44.40M | -60.61M | 10.90M | -41.61M | 4.17M | -5.65M | -63.87M | -42.48M | -99.26M | -7.38M | -10.18M | -11.53M | -10.49M | -15.86M | -12.90M |
| Net Income | -121 | 634.66K | 1.12M | 6.37M | -12.11M | -46.33M | -81.54M | -64.48M | 49.94M | -62.87M | 47.83M | 4.80M | -64.02M | -47.95M | -93.88M | -22.01M | -6.49M | -16.10M | -19.75M | -24.52M | -23.08M |
| Diluted EPS | - | - | - | - | - | -2.52 | - | -2.69 | 0.40 | -0.48 | 0.32 | 0.03 | -4.12 | -2.72 | -4.98 | -1.03 | -0.30 | -0.73 | -0.84 | -1.02 | -0.88 |
| R&D Expense | - | - | - | - | - | 11.22M | 16.99M | 22.91M | 23.77M | 21.67M | 25.35M | 20.35M | 16.95M | 8.60M | 5.18M | 5.84M | 3.80M | 3.92M | 3.73M | 3.35M | 4.60M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 14.28M | 21.34M | 17.98M | 22.77M | 54.22M | 26.55M |
| Gross Profit | - | 9.35M | 11.68M | -1.69M | 6.75M | - | - |
| Operating Income | -564.34K | -151.93M | -109.06M | -25.60M | -192.29M | -38.36M | -61.31M |
| Net Income | 2.51M | -208.23M | -100.12M | 14.19M | -196.29M | -57.89M | -91.72M |
| Diluted EPS | - | - | -1.49 | 0.95 | -11.02 | -2.64 | -3.59 |
| R&D Expense | - | 52.71M | 88.35M | 78.36M | 30.46M | 17.39M | 15.03M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | 174.46K | 291.61M | 431.01M | 414.13M | 401.07M | 143.89M | 132.68M | 107.33M |
| Total Equity | 23.90K | -327.42M | -531.40M | 99.42M | 198.90M | 40.96M | 8.84M | -38.06M |
| Cash & Equivalents | 24.71K | 917.01K | 54.31M | 37.24M | 13.97M | 227.00K | 738.00K | 6.17M |
| Total Liabilities | 150.56K | 11.04M | 412.30M | 314.71M | 202.16M | 102.93M | 123.84M | 145.39M |
| Current Liabilities | 150.56K | 229.09K | 26.68M | 26.23M | 62.09M | 67.30M | 53.68M | 80.76M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.10M | -63.19M | -110.10M | -137.88M | -38.69M | -6.40M | -13.25M |
| Investing Cash Flow | -286.85M | -12.81M | -5.90M | -5.24M | -4.05M | 514.00K | - |
| Financing Cash Flow | 288.84M | 102.01M | 98.56M | 119.84M | 24.09M | 6.70M | 18.65M |
| Capital Expenditure | - | -27.83M | -6.20M | -5.24M | -1.05M | -161.00K | - |
| Free Cash Flow | - | -91.03M | -116.30M | -143.11M | -39.73M | -6.56M | - |
| Share Buybacks | - | 256.00K | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | 65.5% | 54.8% | -9.4% | 29.7% | - | - |
| Operating Margin % | - | -1,064.0% | -511.2% | -142.4% | -844.4% | -70.7% | -230.9% |
| Net Margin % | - | -1,458.4% | -469.3% | 79.0% | -862.0% | -106.8% | -345.4% |
| ROE % | -0.8% | 39.2% | -100.7% | 7.1% | -479.2% | -655.1% | 241.0% |
| ROCE % | -0.2% | -37.6% | -28.1% | -7.6% | -251.1% | -48.6% | -230.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CELU
Celularity Inc. (CELU) warrants delisted and deregistered from Nasdaq exchange - Stock Titan
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOWUk4cmxxRzM1QjM1NVJqUElON1NpcnBrZFhkNlJBTlZ1b042RC1teUNEVDNHOXBSRk1xUDVzX1YxTHpEOWZlWlMwQU9WWHZMTjZwcGRpWHNwSlZDZ2k0aURQS3dmaUF2VDJjdFM3anhsX2pYUkxrNlRJS2NBZG5NVEFNU1h6R1NOUEtaQU…
Celularity Inc. Notified of Non-Compliance with Nasdaq Listing Rule Due to Delayed 10-Q Filing | CELU Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNWi1OTkNLNVlKOVNvMFlvTE1QdlVjZmtYdW5Gd182QWJtX2FadTA1NTNDeE5wVVhVbmhfWEFwRUdpRzQzYW5qbm9DOGpVU001ZGpyY180ZXpfMGVhNXZNd2pCOS1UdGVpcGNLVTF4aVg5YURqLUlJYWdlcENKUEoxWWxsY2YtemFXZkhJaE…
CELU|Celularity Inc|Price:0.635|Chg%:-0.045 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9xdm1oVFFoQ3hPTFVjZDZCbEY5STg2aUFnM25KbTB0dVJHWDlRZ2ZxVDM3SDlndnlmbEVvd3V1dThoUll0VWVZRndOdm1UYXdwZUtWVFJnSkFNYW5mR1V4UUpSYWhzWHZhQUExd3dB?oc=5" target="_blank">CELU|Celularity Inc…
Stocks to watch on Friday after hours: CTLP, CELU, ULH (CTLP:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOOXhHaTVHcGdjYm9jbFJXdXRFNVZYcnNFbEhiUjQwM2VLckp1SXQ2YTRadF9tb1dZbDNyVlBlRHpxSUpGZmJzaktHQmdjdWZWemlhSlRiUUpKM2RZbVViOExrdVl1NFYyWTZrYVZtdlFIUXhxc0NNOW9tbTcwTkwyU3JTLUhINHdPdGtPam…
There Is A Reason Celularity Inc.'s (NASDAQ:CELU) Price Is Undemanding - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxPSFFtcXJXdGxKX3N0T3FSZkFscXFKVWM1OWtDVXIySG95YzNqSVYycGhlNWwtUmJ2SV9RZDhjQTc3NWpQX2QxclplU0E1OU1CUmNFczhOVnBiUFhucG1GNHVCeXFOdVJ6XzhCWHF4TG8xbzduYjBWXzQyUm9uR0ota0FGNEthNDZOU1Ztay…
Celularity Strengthens Leadership With New Executive Appointments - theglobeandmail.com
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxNc0x2OW9qN0UyVGZpV2xfek9yRjVkTUNKVmZ4eHlHa0FxdEhwa1RNZHV2OFBMeHBzQnpoQUdGSVhiR1d4b2xqZE1CUGlGcmdheHVLbm1yOWFwUDVEZkJuUFhmMGZiMWhqT2J2NjgxLTFQMnZyQmY3RHd6a184Ri1HUG1yLXJZS3NoWC0ya2…
CELU — Frequently Asked Questions
What is the current share price of CELU?
As of 2026-08-05 17:25 PDT, CELU trades at $0.73 on NASDAQ/NYSE. Its 52-week range is $0.60 to $4.15.
What is the P/E ratio of CELU?
CELU trades at a trailing price-to-earnings (P/E) ratio of -0.20.
Is CELU a good stock to buy?
This page provides a data-driven analysis of CELU, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.